Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical efficacy and safety of sintilimab (one
anti-PD-1 antibody same as nivolumab approved in China) in combination with bevacizumab in
patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab
with or without PTEN or TERT gene mutations.